FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307141079> ?p ?o ?g. }

• W4307141079 endingPage "e611" @default.
• W4307141079 startingPage "e611" @default.
• W4307141079 abstract "<h3>Purpose/Objective(s)</h3> Neoadjuvant chemotherapy (NACT) is often used for tumor downstaging in locally advanced colon cancer (LACC) and improves the R0 resection rate. Based on previous findings, we hypothesized that neoadjuvant chemoradiotherapy (NACRT) might bring a higher R0 resection rate and survival benefit to patients with unresectable LACC. Our perspective study aimed at comparing NACRT versus NACT for unresectable LACC to confirm our hypothesis. <h3>Materials/Methods</h3> We performed the world's first randomized controlled phase 3 trial on NACRT for LACC at our institution. Eligible patients had newly diagnosed unresectable LACC. We randomly allocated patients open-label to the NACT group (control group) or the NACRT group (research group). Chemotherapy regimen was XELOX (oxaliplatin 100-130mg/m2, iv drip, d1, every 3 weeks; capecitabine 1,000mg/m2, bid, d1-d14, every 3 weeks). Patients allocated radiotherapy received a daily irradiation schedule (GTV:50Gy/25F/5W, CTV:45Gy/25F/5W). Surgery scheduled 6–8 weeks after radiotherapy and adjuvant chemotherapy were given if patients transformed into resectable LACC. <h3>Results</h3> Between July 2019 and July 2021, 49 patients with unresectable LACC underwent randomization and 45 patients (4 excluded) were analyzed for efficacy finally. There were 23, 6, 8, 7 and 1 patients with primary tumor location at sigmoid colon, descending colon, transverse colon, ascending colon and ileocecus. The median follow-up time was 20.7 months. Allocated groups were balanced, with 25 patients receiving NACRT and 20 patients receiving NACT. Twenty-one (84%) patients in the NACRT group transformed to resectable LACC after planned neoadjuvant treatment and received surgery while there were only 5 (20%) patients in the NACT group. Compared to NACT, the use of NACRT improved the R0 resection rate (80% vs 20%) significantly. The 2-year progression-free survival is 72.2% in the NACRT group and 37.4% in the NACT group (p=0·029). The 2-year overall survival is 95.5% in the NACRT group and 73.1% in the NACT group (p=0·035). No increasing toxicities and postsurgical complications were observed from the NACRT group compared with the NACT group. The trial is terminated since the R0 resection rate and survival between the two groups had shown a significant difference. Also, the patients' MMR/MSI status was not considered at the beginning of the study design. <h3>Conclusion</h3> Based on neoadjuvant chemotherapy, the addition of radiotherapy provided a higher R0 resection rate, longer progression-free survival and even might improve overall survival for patients with unresectable LACC. We concluded that this approach is safe, feasible and might associate with a better survival benefit. We are designing new clinical studies to further demonstrate the value of NACRT in LACC. This trial is registered with ClinicalTrials.gov, number NCT03970694." @default.
• W4307141079 created "2022-10-28" @default.
• W4307141079 creator A5007495243 @default.
• W4307141079 creator A5008881420 @default.
• W4307141079 creator A5009666175 @default.
• W4307141079 creator A5013860208 @default.
• W4307141079 creator A5015567420 @default.
• W4307141079 creator A5031770157 @default.
• W4307141079 creator A5044639816 @default.
• W4307141079 creator A5046161181 @default.
• W4307141079 creator A5050781324 @default.
• W4307141079 creator A5061540453 @default.
• W4307141079 date "2022-11-01" @default.
• W4307141079 modified "2023-09-26" @default.
• W4307141079 title "Neoadjuvant Chemoradiotherapy Significantly Improved R0 Resection Rate in Unresectable Locally Advanced Colon Cancer: The Initial Analysis from the Randomized Controlled Phase 3 Trial" @default.
• W4307141079 doi "https://doi.org/10.1016/j.ijrobp.2022.07.1823" @default.
• W4307141079 hasPublicationYear "2022" @default.
• W4307141079 type Work @default.
• W4307141079 citedByCount "0" @default.
• W4307141079 crossrefType "journal-article" @default.
• W4307141079 hasAuthorship W4307141079A5007495243 @default.
• W4307141079 hasAuthorship W4307141079A5008881420 @default.
• W4307141079 hasAuthorship W4307141079A5009666175 @default.
• W4307141079 hasAuthorship W4307141079A5013860208 @default.
• W4307141079 hasAuthorship W4307141079A5015567420 @default.
• W4307141079 hasAuthorship W4307141079A5031770157 @default.
• W4307141079 hasAuthorship W4307141079A5044639816 @default.
• W4307141079 hasAuthorship W4307141079A5046161181 @default.
• W4307141079 hasAuthorship W4307141079A5050781324 @default.
• W4307141079 hasAuthorship W4307141079A5061540453 @default.
• W4307141079 hasConcept C121608353 @default.
• W4307141079 hasConcept C126322002 @default.
• W4307141079 hasConcept C141071460 @default.
• W4307141079 hasConcept C168563851 @default.
• W4307141079 hasConcept C2776694085 @default.
• W4307141079 hasConcept C2777909004 @default.
• W4307141079 hasConcept C2778292576 @default.
• W4307141079 hasConcept C2778336483 @default.
• W4307141079 hasConcept C2778424827 @default.
• W4307141079 hasConcept C2780456651 @default.
• W4307141079 hasConcept C2780962732 @default.
• W4307141079 hasConcept C2781413609 @default.
• W4307141079 hasConcept C509974204 @default.
• W4307141079 hasConcept C526805850 @default.
• W4307141079 hasConcept C530470458 @default.
• W4307141079 hasConcept C71924100 @default.
• W4307141079 hasConceptScore W4307141079C121608353 @default.
• W4307141079 hasConceptScore W4307141079C126322002 @default.
• W4307141079 hasConceptScore W4307141079C141071460 @default.
• W4307141079 hasConceptScore W4307141079C168563851 @default.
• W4307141079 hasConceptScore W4307141079C2776694085 @default.
• W4307141079 hasConceptScore W4307141079C2777909004 @default.
• W4307141079 hasConceptScore W4307141079C2778292576 @default.
• W4307141079 hasConceptScore W4307141079C2778336483 @default.
• W4307141079 hasConceptScore W4307141079C2778424827 @default.
• W4307141079 hasConceptScore W4307141079C2780456651 @default.
• W4307141079 hasConceptScore W4307141079C2780962732 @default.
• W4307141079 hasConceptScore W4307141079C2781413609 @default.
• W4307141079 hasConceptScore W4307141079C509974204 @default.
• W4307141079 hasConceptScore W4307141079C526805850 @default.
• W4307141079 hasConceptScore W4307141079C530470458 @default.
• W4307141079 hasConceptScore W4307141079C71924100 @default.
• W4307141079 hasIssue "3" @default.
• W4307141079 hasLocation W43071410791 @default.
• W4307141079 hasOpenAccess W4307141079 @default.
• W4307141079 hasPrimaryLocation W43071410791 @default.
• W4307141079 hasRelatedWork W2032042555 @default.
• W4307141079 hasRelatedWork W2357672316 @default.
• W4307141079 hasRelatedWork W2375984193 @default.
• W4307141079 hasRelatedWork W2393506218 @default.
• W4307141079 hasRelatedWork W2418334170 @default.
• W4307141079 hasRelatedWork W2592176478 @default.
• W4307141079 hasRelatedWork W2888675743 @default.
• W4307141079 hasRelatedWork W3044474789 @default.
• W4307141079 hasRelatedWork W4254058797 @default.
• W4307141079 hasRelatedWork W4307141079 @default.
• W4307141079 hasVolume "114" @default.
• W4307141079 isParatext "false" @default.
• W4307141079 isRetracted "false" @default.
• W4307141079 workType "article" @default.